Form 4 | Pasithea Therapeutics Corp. Director Lawrence Steinman purchased 133,333 Shares.

Filings Track

Dec 01

Lawrence Steinman, Director of Pasithea Therapeutics Corp. (Ticker: KTTA), on November 28, 2025, purchased 133,333 shares of common stock at a price of $0.75 per share. After the transaction, Mr. Steinman holds a total of 199,691 shares of common stock. The purchase by executives and directors is usually regarded as a sign of confidence in the company's prospects, which may positively impact the company's stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1100736610"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100736610\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100736610?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 22:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100736610","market":"us","top_or_hot":-1,"title":"Form 4 | Pasithea Therapeutics Corp. Director Lawrence Steinman purchased 133,333 Shares.","media":"Filings Track","content":"Lawrence Steinman, Director of Pasithea Therapeutics Corp. (Ticker: KTTA), on November 28, 2025, purchased 133,333 shares of common stock at a price of $0.75 per share. After the transaction, Mr. Steinman holds a total of 199,691 shares of common stock. The purchase by executives and directors is usually regarded as a sign of confidence in the company's prospects, which may positively impact the company's stock price.","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Form 4 | Pasithea Therapeutics Corp. Director Lawrence Steinman purchased 133,333 Shares.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForm 4 | Pasithea Therapeutics Corp. Director Lawrence Steinman purchased 133,333 Shares.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1033292654\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/f241068b466f5f9316243a75366834d5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Filings Track </p>\n<p class=\"h-time\">2025-12-01 22:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\nLawrence Steinman, Director of Pasithea Therapeutics Corp. (Ticker: KTTA), on November 28, 2025, purchased 133,333 shares of common stock at a price of $0.75 per share. After the transaction, Mr. Steinman holds a total of 199,691 shares of common stock. The purchase by executives and directors is usually regarded as a sign of confidence in the company's prospects, which may positively impact the company's stock price.\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KTTA","symbol_name":"Pasithea Therapeutics Corp.","start_time":0,"source_url":"","article_id":"1100736610","we_media_id":"1033292654","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100736610","pubTimestamp":1764598216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Filings Track","introduction":"Stay Updated with Major Exchanges' Announcements","home_visible":1,"id":"1033292654","head_image":"https://static.tigerbbs.com/f241068b466f5f9316243a75366834d5"},"summary":"Lawrence Steinman, Director of Pasithea Therapeutics Corp. (Ticker: KTTA), on November 28, 2025, purchased 133,333 shares of common stock at a price of $0.75 per share. After the transaction, Mr....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KTTA":"Pasithea Therapeutics Corp."},"translate_title":"表格4|Pasithea Therapeutics Corp.董事Lawrence Steinman购买了133,333股股票。","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KTTA":1},"content_text":"Lawrence Steinman, Director of Pasithea Therapeutics Corp. (Ticker: KTTA), on November 28, 2025, purchased 133,333 shares of common stock at a price of $0.75 per share. After the transaction, Mr. Steinman holds a total of 199,691 shares of common stock. The purchase by executives and directors is usually regarded as a sign of confidence in the company's prospects, which may positively impact the company's stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"insiderTrades","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}